CINECA IRIS Institutional Research Information System

NUTI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.432
EU - Europa 3.328
AS - Asia 1.165
AF - Africa 111
SA - Sud America 11
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.056
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.228
IT - Italia 1.281
CN - Cina 638
SE - Svezia 524
DE - Germania 456
BG - Bulgaria 361
GB - Regno Unito 205
CA - Canada 199
TR - Turchia 170
VN - Vietnam 144
FI - Finlandia 114
UA - Ucraina 105
FR - Francia 99
IN - India 66
SN - Senegal 66
SG - Singapore 65
RU - Federazione Russa 44
BE - Belgio 30
CH - Svizzera 30
NG - Nigeria 30
AT - Austria 28
HK - Hong Kong 27
ES - Italia 12
CI - Costa d'Avorio 11
JP - Giappone 11
TW - Taiwan 11
KR - Corea 9
BR - Brasile 8
IR - Iran 8
GR - Grecia 7
CZ - Repubblica Ceca 6
IE - Irlanda 6
MX - Messico 5
NL - Olanda 5
PL - Polonia 5
AU - Australia 4
PK - Pakistan 4
HR - Croazia 3
HU - Ungheria 3
ID - Indonesia 3
IL - Israele 3
MA - Marocco 3
EU - Europa 2
MY - Malesia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
CL - Cile 1
EC - Ecuador 1
JO - Giordania 1
LT - Lituania 1
ML - Mali 1
NO - Norvegia 1
RO - Romania 1
SI - Slovenia 1
VE - Venezuela 1
Totale 12.056
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.068
Ann Arbor 910
Chandler 725
Fairfield 688
Houston 686
Ashburn 398
Sofia 361
Serra 330
Seattle 293
Milan 279
Wilmington 267
Beijing 252
New York 220
Cambridge 216
Ottawa 189
Princeton 173
Izmir 161
Jacksonville 138
Lawrence 138
Medford 120
Nanjing 119
Des Moines 105
Florence 100
Bremen 93
London 92
Dong Ket 78
Dakar 66
Frankfurt am Main 47
Pisa 47
Marseille 41
Nanchang 41
Redwood City 37
Dearborn 35
Rome 33
Hebei 31
Lagos 30
San Diego 30
Bern 29
Brussels 28
Vienna 28
Los Angeles 27
Lancaster 26
Kunming 25
Hong Kong 24
Pessac 24
Boulder 23
Changsha 23
Livorno 23
Nürnberg 23
Pune 23
Alessandria 19
Hefei 19
Jüchen 18
Jiaxing 17
Norwalk 17
Shenyang 17
Auburn Hills 16
Ogden 15
Boardman 14
Falls Church 13
Abidjan 11
Hangzhou 11
Tianjin 11
Washington 11
Kaohsiung 10
Dallas 9
Guangzhou 9
San Francisco 9
Talence 9
Seelze 7
Indiana 6
Lucca 6
Phoenix 6
San Giuliano Terme 6
Shanghai 6
Tappahannock 6
Toronto 6
Düsseldorf 5
Jinan 5
Leawood 5
Napoli 5
Pardubice 5
Paris 5
Baotou 4
Cadoneghe 4
Capannoli 4
Cerveteri 4
Dublin 4
Edinburgh 4
Fremont 4
Lanzhou 4
Naples 4
Orange 4
Potsdam 4
São Paulo 4
Tarragona 4
Tokyo 4
Wuhan 4
Zhengzhou 4
Calci 3
Totale 9.364
Salva come PNG Salva come JPEG
Nome #
ADAMs and ADAMTs selective synthetic inhibitors 170
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization 161
N-(aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase 147
INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE 142
A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer 137
ADAM metalloproteinases as potential drug targets 134
Benzo[d]isothiazoles and Matrix Metalloproteinases. Searching for Novel and Selective Inhibitors of MMP9 131
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity 127
Drug design of sulfonylated MMP inhibitors 123
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides 123
Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds 123
Synthetic analogs of xanthohumol for use in the prevention and​/or treatment of tumors 122
Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models 120
Arylsulfonamide derivatives as metalloproteases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of degenerative disorders 120
N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors 119
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors 119
New bifunctional metalloproteinase inhibitors: an integrated approach towards biological improvements and cancer therapy. 119
Crystallization of bi-functional ligand protein complexes 119
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins 118
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs 117
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 117
In Vivo Imaging of Matrix Metalloproteinase 12 and Matrix Metalloproteinase 13 Activities in the Mouse Model of Collagen-Induced Arthritis 117
null 116
Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-a Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models 116
Immobilization of matrix metalloproteinase 8 (MMP-8) for online drug screening 115
Aryl-sulphonamidic dimers as metalloproteases inhibitors 114
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis 114
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors 114
Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies 114
Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors 113
Age-related macular degeneration: Current knowledge of zinc metalloproteinases involvement 113
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate-Benzenesulfonamide Conjugates 111
Multitemplate Alignment Method for the Development of a Reliable 3D-QSAR Model for the Analysis of MMP3 Inhibitors 111
Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors 109
Analysis of Human Carbonic Anhydrase II: Docking Reliability and Receptor-Based 3D-QSAR Study 108
Synthesis of New Classes of MMPs Sugars-Based Inhibitors 108
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors 107
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. 107
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors 106
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models 105
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates 103
null 103
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs 103
Powerful twin carboxylic inhibitors for MMP homodimerization 103
Matrix metalloproteinase inhibitors prevent the release and proteolytic activity of monocyte/macrophage-derived microparticles 103
Design of selective collagenase 3 (MMP-13) inhibitors as potential therapeutic agents in rheumatoid arthritis 102
Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity 102
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP) 102
MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions 102
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP 101
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma 101
Amino Acid Derivatives as New Zinc Binding Groups for the Design of Selective Matrix Metalloproteinase Inhibitors 100
1-(PHENYLSULPHONAMIDO)-PYRAZOLE DERIVATIVES AS CARBONIC ANHYDRASE INHIBITORS. 99
Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues 99
Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors 99
Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates 98
Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido Groups 97
A new small molecule, D2 dopamine receptor agonist, as an allosteric modulator of A2A adenosine receptor signalling 96
Synthesis and Preliminary Evaluation in Tumor Bearing Mice of New 18F‑Labeled Arylsulfone Matrix Metalloproteinase Inhibitors as Tracers for Positron Emission Tomography 95
Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide 94
Arylsulfonamido compounds as metalloprotease inhibitors and their preparation, pharmaceutical compositions and use as diagnostic as well as radiotherapeutic agents 94
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases 93
Effects of selective MMP-2 inhibitors on viability and invasiveness in the U87MG human glioblastoma cell line 91
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF NEW 7BETA-(BENZO[A]DIHYDROCARBAZOLYLOXYACETYL)-SUBSTITUTED CEPHALOSPORINS 91
Design and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles 89
Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent MMP-12 inhibitors 88
null 88
Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators 88
Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent MMP-12 inhibitors 87
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization 86
Ionic liquid-promoted green synthesis of biologically relevant diaryl thioethers 86
Novel Peptidomimetic as MMP-2 Inhibitors 84
Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies 83
Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes 83
Molecular Underpinnings of MMP-13 Selective Inhibition by Arylsulfonamido Hydroxamate Analogues as Potential Therapeutic Agents in Osteoarthritis 82
Discovery of a new subnanomolar Tumor Necrosis Factor-alpha Converting Enzyme (TACE) inhibitor as antiinvasive agent 82
A new small molecule, D2 dopamine receptor agonist, as an allosteric modulator of A2A adenosine receptor signalling 82
D2 dopamine receptor agonists as allosteric modulators of A2A adenosine receptor signalling 80
Inhibition of pseudolysin and thermolysin by hydroxamate-based MMP inhibitors 80
Arylsulfonamide derivatives, especially dimeric hydroxamic acid-​containing amino acids, metalloproteases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of degenerative disorders 79
Design, synthesis and biological properties of new potent and selective sulfonamide-based inhibitors of gelatinase A 78
Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit a- and ß-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms 78
Design, Synthesis and Inhibitory Properties of Potent Sulfonyl Diaryl Based MMPs and TACE inhibitors 77
Analoghi sintetici dello xantumolo 76
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins 75
New chromane, thiocromane and tetrahydronaphtalene oxime ether derivatives combining SERT and a2-adrenoceptor affinity 74
null 74
New arylsulfonamido-based MMP inhibitors with improved water solubility 74
Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays 74
Targeting ADAM17 Sheddase Activity in Cancer 73
New 18F-Labelled Inhibitors of Matrix Metalloproteinases as Imaging Probes for PET Imaging 71
null 71
Design of Selective Collagenase 3 (MMP-13) Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis 70
Sintesi e Valutazione Biologica di Acidi Aril-Solfonil-Fosfonici come Inibitori Selettivi delle Metalloproteinasi di Matrice (MMP) 69
NMR STUDIES OF A NEW POTENT MMP-12 INHIBITOR: INSIGHT INTO KEY BINDING INTERACTIONS 69
Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation 69
null 69
Synthesis and cycloxygenase inhibitory activity of new naphthalene-methylsulfonamido and naphthalene-methylsulfonyl compounds. 68
Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis 68
Inhibition of matrix degrading enzymes and invasion in rat glioblastoma (C6) cells 67
Totale 9.988
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019429 0 0 0 0 0 0 0 0 0 0 248 181
2019/20201.917 245 158 113 121 156 194 225 134 163 165 187 56
2020/20211.096 77 62 28 40 122 135 52 101 116 90 62 211
2021/20221.590 30 179 34 63 287 218 46 74 49 40 85 485
2022/20232.238 251 270 147 283 236 266 13 166 403 11 151 41
2023/20241.258 163 137 149 93 192 292 72 69 24 33 34 0
Totale 12.359